By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
Juno (JUNO) Awards CEO, CFO Special Bonus After $1 Billion Celgene (CELG) Deal 2/8/2016 2:32:20 PM
Juno (JUNO) Awards CEO, CFO Special Bonus After $1 Billion Celgene (CELG) Deal 2/8/2016 2:32:20 PM
Juno (JUNO) To Present At The Leerink Partners 5th Annual Global Healthcare Conference 2/4/2016 9:28:25 AM
Juno (JUNO) Pays $125 Million for Harvard Spinout AbVitro 1/11/2016 11:21:20 AM
Juno (JUNO) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/7/2016 11:42:41 AM
Eureka Therapeutics Announces Exclusive License Agreement Between Memorial Sloan-Kettering Cancer Center And Juno (JUNO) For Use Of A Novel, Fully-Human MUC16 Binder In CAR T Cell Immunotherapy 1/7/2016 7:50:40 AM
Juno (JUNO)’s Investigational CAR T Product Candidates JCAR014 And JCAR018 Demonstrate Encouraging Clinical Responses In Patients With B-Cell Cancers 12/7/2015 10:27:00 AM
Juno (JUNO) Announces Data Presentations At The American Society of Hematology Annual Meeting 12/1/2015 10:18:33 AM
Juno (JUNO) Reports Third Quarter 2015 Financial Results 11/11/2015 10:37:47 AM
Juno (JUNO) To Present At The Credit Suisse 24th Annual Healthcare Conference 11/6/2015 11:28:02 AM
123456789
//-->